The links below describe cancer research efforts that were seed funded by the GAC at the University of Houston. This first paper (Tennakoon et al) was initially published in 2013 but the final format was published in print the following year. The second is a review article co-authored by Daniel E. Frigo, Ph.D., Assistant Professor, University of Houston Center for Nuclear Receptors & Cell Signaling
Department of Biology & Biochemistry and Dr. Andrew Schally who is the Head of The Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, Research Services South Florida, VA Foundation for Research and Education. Andrew Schally won the 1977 Nobel Prize in Physiology or Medicine for his work that led to the discovery of the one of the standards of care treatment for advanced prostate cancer—hormone ablation therapy/chemical castration. The third paper has been one of that journal’s Top Ten Most Downloaded papers since the second month after it was published (over 1.5 years). Collectively, these also helped set the foundation for our recent larger R01 grant and the GAC is credited in all for support.
In addition, here are two links that further describe/acknowledge progress on our University of Houston’s GAC-funded research. The GAC funded first award (Development of a CaMKKbeta-Selective Antagonist for the Treatment of Advanced Prostate Cancer) set the foundation for an initial $337,000 award from the Department of Defense/Prostate Cancer Research Program (DOD/PCRP). This is highlighted in the following link: CNRCS Investigators Awarded Additional Funding from NIH, DOD. This grant just ended and the progress made on this project is being highlighted by the DOD in their FY2016 newsletter.
Next, the data generated from the GAC and DOD funded project just led earlier this year to the awarding of a much larger ~$1.9 million grant from the NIH/NCI. A description of this can be found in the following link: New Prostate Cancer Treatments Could Target Metabolism.